View Older Stories View More Recent Stories

May 17, 2021 08:05AM Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS,
May 17, 2021 08:05AM Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS,
May 14, 2021 06:08AM Aeterna Zentaris (AEZS) Begins Pivotal Phase 3 DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 13, 2021 08:05AM Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 13, 2021 08:05AM Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 10, 2021 08:05AM Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
May 10, 2021 08:05AM Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
May 6, 2021 08:17AM Aeterna Zentaris (AEZS) Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 6, 2021 08:05AM Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 6, 2021 08:05AM Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 5, 2021 04:35PM Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 5, 2021 04:35PM Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 5, 2021 08:05AM Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 5, 2021 08:05AM Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 3, 2021 08:05AM Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
May 3, 2021 08:05AM Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
Apr 28, 2021 08:05AM Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
Apr 28, 2021 08:05AM Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
Mar 25, 2021 08:05AM Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 25, 2021 08:05AM Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 22, 2021 04:07PM Aeterna Zentaris (AEZS) Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mar 22, 2021 04:05PM Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mar 22, 2021 04:05PM Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mar 15, 2021 08:16AM Aeterna Zentaris (AEZS) Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Agai
Mar 15, 2021 08:05AM Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COV
Mar 15, 2021 08:05AM Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COV
Mar 11, 2021 08:14AM Aeterna Zentaris (AEZS) Announces Initiation of Its Preclinical Program for Potential Treatment of Primary Hypoparathyroidism
Mar 11, 2021 08:05AM Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
Mar 11, 2021 08:05AM Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
Feb 24, 2021 08:05AM Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 24, 2021 08:05AM Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 19, 2021 01:25PM Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
Feb 19, 2021 01:25PM Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
Feb 16, 2021 10:00PM Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
Feb 16, 2021 10:00PM Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
Feb 16, 2021 05:20PM Aeterna Zentaris (AEZS) Announces $10 Million Bought Deal Offering of Common Shares
Feb 16, 2021 05:19PM Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
Feb 16, 2021 05:19PM Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
Feb 2, 2021 07:38AM Aeterna Zentaris (AEZS) Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University
Feb 2, 2021 07:30AM Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzbu
Feb 2, 2021 07:30AM Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzbu
Jan 28, 2021 08:05AM Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
Jan 28, 2021 08:05AM Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
Jan 26, 2021 04:05PM Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Jan 26, 2021 04:05PM Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Jan 15, 2021 08:05AM Aeterna Zentaris to Present at NobleCon17
Jan 15, 2021 08:05AM Aeterna Zentaris to Present at NobleCon17
Jan 5, 2021 08:05AM Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Jan 5, 2021 08:05AM Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Dec 7, 2020 08:10AM Aeterna Zentaris (AEZS) Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
View More Recent Stories View Older Stories